Official Title
COVID-19 in Patients With Chronic Liver Diseases
Brief Summary

This study seeks to determine how COVID-19 affects the clinical outcome of patients with chronic liver disease, and whether the clinical course of COVID-19 is influenced by underlying chronic liver disease.

Completed
COVID-19
Chronic Liver Disease

Other: Prospective Chart Review

Collected data will include demographic features, clinical characteristics, clinical outcome, medication use, COVID-19-related complications in patients with chronic liver disease.

Eligibility Criteria

Inclusion Criteria:

- Confirmed diagnosis of COVID-19

- Personal history of either

- Chronic hepatitis C

- Chronic hepatitis B

- Alcoholic liver disease

- Non alcoholic liver disease

- Autoimmune hepatitis, Primary biliary cholangitis, Primary sclerosing cholangitis

- Cryptogenic cirrhosis

- Hepatocellular carcinoma

Exclusion Criteria:

- Non-COVID-19 patient

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
United States
Locations

University of Arizona,
Phoenix, Arizona, United States

Mayo Clinic
Scottsdale, Arizona, United States

UCSF Fresno
Fresno, California, United States

University of Southern California
Los Angeles, California, United States

Stanford University
Stanford, California, United States

Georgetown University
Washington, District of Columbia, United States

VA Medical Center
Washington, District of Columbia, United States

University of Miami
Miami, Florida, United States

Rush University Medical Center
Chicago, Illinois, United States

The University of Kansas Medical Center
Kansas City, Kansas, United States

Oschner Medical Center
Baton Rouge, Louisiana, United States

Massachusetts General Hospital
Boston, Massachusetts, United States

Brigham and Women's Hospital
Boston, Massachusetts, United States

Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States

University of Michigan
Ann Arbor, Michigan, United States

Hennepin County Medical Center (HCMC)
Minneapolis, Minnesota, United States

University of Minnesota
Minneapolis, Minnesota, United States

Mount Sinai School of Medicine
New York, New York, United States

Weill Cornell Medicine
New York, New York, United States

Duke University
Durham, North Carolina, United States

University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States

University of Pennsylvania
Philadelphia, Pennsylvania, United States

University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States

Renumathy Dhanasekaran, MD, Principal Investigator
Stanford University

Stanford University
NCT Number
MeSH Terms
COVID-19
Liver Diseases